MedTrace Logo

OVArian Cancer Non-Interventional Study - OVATAR

NCT02122588 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 503

Last updated 2019-05-21

No results posted yet for this study

Summary

This is a multicentre, non-interventional, prospective study to be carried out in representative hospitals in order to assess 1st line treatment management and diagnostic approaches applied to ovarian, peritoneal and fallopian tube cancer management in Russia and assess patients' characteristics and the occurrence of BRCA (Breast Cancer gene) mutations among Russian women with serous and endometrioid ovarian, peritoneal and fallopian tube cancer. No additional procedures besides those already used in the routine clinical practice will be applied to the patients. Treatment assignment will be done according to the current practice.

Conditions

  • Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia

Sponsors & Collaborators

  • RUSSCO (Russian Society of Clinical Oncology)

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Karin Otter · AstraZeneca

  • Vera Gorbunova · Russian Cancer Research Center named after NN Blokhin

  • Alexandra Tyulandina · Russian Cancer Research Center named after NN Blokhin

  • Larisa Kolomietz · Research Oncology Center, Tomsk

  • Tatiana Kekeeva · Research Centre for Medical Genetics, Moscow

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02122588 on ClinicalTrials.gov